Non-regulatory press release

The 28[th] of March is the last day of trading in TO 2

The exercise period for Prostatype Genomics AB's ("Prostatype Genomics" or "the Company") warrants of series TO 2 ("TO 2") lasts until March 30, 2023, and the last day for trading in TO 2 is March 28, 2023. Holders of TO 2 have the right to subscribe for one new share in Prostatype Genomics at a price of SEK 2.90 per share for each warrant. An information sheet is available on the respective websites of Prostatype Genomics (, Sedermera Corporate Finance AB ( and Nordic Issuing AB (

TO 2 in brief

Advisors and issuing agent

Sedermera Corporate Finance AB is the financial advisor and Nordic Issuing AB is the issuing for Prostatype Genomics in connection with the warrant exercise. Markets & Corporate Law Nordic AB is the legal advisor.

For further information about TO 2, please contact

Sedermera Corporate Finance AB

Phone: +46 (0) 40 615 14 10



Nordic Issuing AB

Phone: +46 (0) 40 632 00 20



For further information about Prostatype Genomics, please contact

Nicklas Rosendal


Certified Advisor

Svensk Kapitalmarknadsgranskning AB

Phone: +46 (0) 11-32 30 732


Prostatype® is a genetic test that is available to patients and treating urologists as a supplementary decision basis for the question of treatment or not treatment of prostate cancer. The test is developed by a research group at Karolinska Institutet and is provided by Prostatype Genomics AB.